Abbott Laboratories Surprises with Q2 2026 Earnings Beat, Raises Guidance

ABT Abbott Laboratories delivered a Q2 2026 earnings beat, reporting adjusted earnings per share of $1.31, ahead of the roughly $1.29 consensus, on revenue of $12.6 billion. Comparable organic sales grew 4.8% and second-quarter adjusted gross margin expanded about 100 basis points to 58.0% of sales, reflecting steady execution across the company's diversified franchises in medical devices, diagnostics, nutrition and established pharmaceuticals.

Management raised full-year adjusted EPS guidance to a range of $5.45 to $5.60 and reaffirmed comparable sales growth of 6.5% to 7.5%. For the third quarter, Abbott guided to adjusted EPS of $1.38 to $1.46, signaling confidence in second-half momentum led by its diabetes-care and diagnostics businesses.

The upgraded outlook, rather than a decisive top-line surprise, is the story here: revenue landed roughly in line with Street expectations while the EPS beat and guidance raise did the work. Investors will watch continued device growth and the normalization of diagnostics demand as the key swing factors for whether Abbott can sustain the higher full-year targets.

Related Stocks

• ABT
• FDS